Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib ...Middle East

STOCKHOLM, May 6, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced data from the proof-of-concept Phase 2 trial evaluating setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab, in patients with...

Hence then, the article about calliditas announces positive topline results of phase 2 head and neck cancer trial with lead nox inhibitor candidate setanaxib was published today ( Monday 06/05/2024 - 09:17 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib )

Also on site :

• Tayvis Fans Are 'Sobbing' Over 'Precious' Photo of Donna Kelce and Andrea Swift: 'The In-Laws Are Hanging Out'
• China launches investigation into top general – MOD
• If You Say These 7 Things Regularly, People May Think You’re Difficult to Be Around, Psychologists Warn